Dosage schedules of aminoglycosides

Current Opinion in Infectious Diseases

Volumn 9, Issue 6, 1996, Pages 398-402

  Prins, Jan M ^a   Speelman, Peter ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE;

BACTERIAL ENDOCARDITIS; CHILDHOOD DISEASE; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; INFECTION; KIDNEY FAILURE; NEUTROPENIA; REVIEW;

EID: 0030444339     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199612000-00007     Document Type: Review

References (49)

1. Gilbert DN: Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991, 35:399-405.
2. Gilbert DN: Aminoglycosides. In Principles and practice of infectious diseases, edn 4. Edited by Mandell GL, Bennett JE, Dolin R. New York: Churchill Livingstone; 1995:279-306.
3. Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P: Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993, 341:335-339.
4. Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande ME: Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis 1988, 158:7-12.
5. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA: In-vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988, 157:287-298.
6. Vogelman BS, Craig WA: Postantibiotic effects. J Antimicrob Chemother 1985, 15(suppl A):37-46.
7. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME: Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989, 45:22-27.
8. De Broe ME, Verbist L, Verpooten GA: Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991, 27(suppl C):41-47.
9. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxham DD, Groden DL, Jacobs MR, DiScenna AO, Cash HA, Klinger JD: Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983, 147:918-932.
10. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA: The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979, 140:576-580.
11. Tran Ba Huy P, Bernard P, Schacht J: Kinetics of gentamicin uptake and release in the rat Comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986, 77:1492-1500.
12. Prins JM, Koopmans RP, Büller HR, Kuijper EJ, Speelman P: Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Clin Microb Infect Dis 1995, 14:531-535.
13. Gallee AM, Graudal N, Christensen HR, Kampmann JP: Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995, 48:39-43.
14. Blaser J, König C: Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1995, 14:1029-1038.
15. Barza M, Ioannidis JPA, Cappelleri JC, Lau J: Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996, 312:338-345. A good meta-analysis of trials comparing once-a-day versus multiple-daily aminoglycoside dosing.
16. Hatala R, Dinh T, Cook DJ: Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996, 124:717-725. A good meta-analysis of trials comparing once-a-day versus multiple-daily aminoglycoside dosing.
17. Munckhof WJ, Grayson ML, Turnidge JD: A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996, 37:645-663. A good meta-analysis of trials comparing once-a-day versus multiple-daily aminoglycoside dosing.
18. Prins JM, Büller HR: Meta-analysis: the final answer, or even more confusion? [Letter]. Lancet 1996, 348:199.
19. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer: Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993, 119:584-593.
20. Marik PE, Lipman J, Kobilski S, Sribante J: A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991, 28:753-764.
21. Viganó A, Principi N, Brivio L, Tommasi P, Stasi P, Dalla Villa A: Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother 1992, 36:1499-1503.
22. Elhanan K, Siplovich L, Raz R: Gentamicin once-daily versus thrice-daily in children. J Antimicrob Chemother 1995, 35:327-332. The only clinical study available on once-a-day versus thrice-a-day dosing of gentamicin in children.
23. Fantin B, Ebert S, Leggett J, Vogelman B, Craig WA: Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli. J Antimicrob Chemother 1990, 27:829-836.
24. Hansen M, Achen F, Carstensen C, Coolidge J, Dahlager J, Frimodt-Møller N, Kjaersgaard E, Larsen H, Wilkenschildt M, Zador G, Hippe E: Once- versus thrice-daily dosing of netilmicin in febrile immunocompromized patients: a randomized, controlled study of efficacy and safety. J Drug Dev 1988, 1(suppl 3):119-124.
25. Rozdzinski E, Kern WV, Reichle A, Moritz T, Schmeiser T, Gaus W, Kurrle E. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993, 31:585-598.
26. Gavaldà J, Pahissa A, Almirante B, Laguarda M, Crespo E, Pou L, Fernández F: Effect of gentamicin dosing interval on therapy of viridans streptococcal experimental endocarditis with gentamicin plus penicillin. Antimicrob Agents Chemother 1995. 39:2098-2103.
27. Saleh-Mghir A, Cremieux AC, Vallois JM, Muffat-Joly M, Devine C, Carbon C: Optimal aminoglycoside dosing regimen for penicillin-tobramycin synergism in experimental Streptococcus adjacens endocarditis. Antimicrob Agents Chemother 1992, 36:2403-2407.
28. Bugnon D, Potel G, Xiong YQ, Caillon J, Kergueris MF, Le Conte P, Baron D, Drugeon H: In-vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model. Antimicrob Agents Chemother 1996, 40:1164-1169.
29. Francioli PB, Glauser MP: Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis. Antimicrob Agents Chemother 1993, 37:207-212.
30. Fantin B, Carbon C: Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother 1990, 34:2387-2391.
31. Gavaldà J, Cardona PJ, Almirante B, Capdevila JA, Laguarda M, Pou L, Crespo E, Pigrau C, Pahissa A: Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Antimicrob Agents Chemother 1996, 40:1 73-178.
32. Francioli P, Ruch W, Stamboulian D, and the International Infective Endocarditis Study Group: Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995, 21:1406-1410. A case series describing 52 patients with streptococcal endocarditis, who were treated with a 2-week course of ceftriaxone plus netilmicin once-a-day.
33. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B: Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984, 105:117-124.
34. Lindsay CA, Bosso JA: Optimisation of antibiotic therapy in cystic fibrosis patients. Clin Pharmacokinet 1993, 24:496-506.
35. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P: Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother 1987, 31:594-599.
36. Wood PJ, Ioannides-Demos LL, Li SC, Williams TJ, Hickey B, Spicer WJ, Hooper RE, McLean AJ: Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996, 51:369-373.
37. Heininger U, Böwing B, Stehr K, Solbach W: Aminoglykoside bei Patienten mit Mukoviszidose und pulmonaler Exazerbation: Vergleich von Einmal- und Dreimalgabe. Klin Pädiatr 1993, 205:18-22.
38. De Vries PJ, Verkooyen RP, Leguit P, Verbrugh HA: Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intra-abdominal infections. Eur J Clin Microbiol Infect Dis 1990, 9:161-168.
39. Maller R, Ahrne H, Holmen C, Lausen I, Nilsson LE, Smedjegård J, and the Scandinavian Amikacin Once Daily Study Group: Once- versus twice-daily amikacin regimen: efficacy and safety in systemic Gram-negative infections. J Antimicrob Chemother 1993, 31:939-948.
40. Sturm AW: Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989, 159:931-937.
41. Ter Braak EW, De Vries PJ, Bouter KP, van der Vegt SG, Dorrestein GC, Nortier JW, van Dijk A, Verkooyen RP, Verbrugh HA: Once-daily dosing regimen for aminoglycoside plus β-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990, 89:58-66.
42. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R: Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995, 39:650-655. The authors describe their experience with the once-a-day administration of aminoglycosides in a very large number of patients, using a fixed daily dose, with a drug administration interval calculated on the basis of the estimated creatinine clearance.
43. McCormack JP, Jewesson PJ: A critical reevaluation of the therapeutic range' of aminoglycosides. Clin Infect Dis 1992, 14:320-339.
44. Moore RD, Smith CR, Lietman PS: Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am J Med 1984, 77:657-662.
45. Moore RD, Smith CR, Lietman PS: The association of aminoglycoside plasma levels with mortality in patients with Gram-negative bacteremia. J Infect Dis 1984, 149:443-448.
46. Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155:93-99.
47. Beaubien AR, Desjardins S, Ormsby E, Bayne A, Carrier K, Cauchy MJ, Henri R, Hodgen M, Salley J, St. Pierre A: Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels. Am J Otolaryngol 1989, 10:234-243.
48. MacGowan A, Reeves D: Serum aminoglycoside concentrations: the case for routine monitoring. J Antimicrob Chemother 1994, 34:829-837.
49. Begg EJ, Barclay ML, Duffull SB: A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995, 39:605-609. The authors propose a simple method to detect an excessive AUC in patients receiving once-a-day aminoglycosides, with the use of one, and in case of renal failure two, serum samples.